Crescita Therapeutics swings to Q2 profit as revenue rises over 50%
Overview
Crescita Q2 revenue rises 52.5% yr/yr, driven by manufacturing and Croma payment
Net income reaches C$798k, reversing a loss from prior year
Adjusted EBITDA improves significantly, reflecting operational efficiencies
Outlook
Crescita exploring partnerships for Pliaglis in European markets
Crescita regained Pliaglis rights in several territories after Croma termination
Company actively seeking new partners for Pliaglis commercialization
Result Drivers
MANUFACTURING VOLUMES - Revenue increase driven by ramp-up of production volumes with new customer in Manufacturing segment
TERMINATION PAYMENT - CAD 900,000 added to revenue from mutual termination agreement with Croma
SKINCARE GROWTH - Skincare segment sales rose due to Aquafolia acquisition and higher export sales
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue |
| C$6.23 mln |
|
Q2 Adjusted EBITDA |
| C$964,000 |
|
Q2 Gross Margin |
| 61.4% |
|
Q2 Operating Expenses |
| C$3.24 mln |
|
Q2 Operating Income |
| C$583,000 |
|
Press Release: ID:nBw7zNX2Na
